Company News Summary | 20 Jan 2022
Click the print icon in your browser to print this report. Currency is in AUD unless otherwise specified
Starpharma Holdings Receives $7.7m R&D Tax Incentive Refund
08:55:00 | Associate analysts
Original annuncemenet:Starpharma receives $7.7M R&D tax incentive refund
Starpharma Holdings announced that it has received a $7.7m research and development (R&D) tax incentive refund related to the Company's Australian and international R&D expenses from the 2021 financial year. The tax refund is for eligible R&D activities across its portfolio, including the Company's DEP oncology products and VIRALEZE antiviral nasal spray.
|This report appeared on www.morningstar.com.au||2022 Morningstar Australasia Pty Limited|
© Copyright 2022 Morningstar Australasia Pty Ltd ABN: 95 090 665 544 ("Morningstar"), AFSL no 240892. (a subsidiary of Morningstar, Inc.). This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written content of Morningstar. Some of the material provided is published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO").